mesalamine, Lialda (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

PREPARATIONS: Tablets: 1.2 g

DRUG INTERACTIONS: Specific drug interaction studies have not been conducted with Lialda. Other mesalamine medications have been associated with several drug interactions. Combining mesalamine with drugs that affect kidney function, for example, nonsteroidal antiinflammatory drugs (for example, ibuprofen), may increase the likelihood of kidney dysfunction. Concurrent use of mesalamine and 6-mercaptopurine or azathioprine (Imuran) may increase the likelihood of blood disorders. Mesalamine may increase the blood thinning effect of warfarin (Warfarin).

PREGNANCY AND BREASTFEEDING SAFETY: There are no adequate human studies of mesalamine use during pregnancy. Mesalamine is known to cross the placenta into the fetus, but animal studies revealed no evidence of harm to the fetus. Mesalamine should only be used during pregnancy if it is felt that the benefit of its use justifies the unknown risks. Mesalamine is excreted in breast milk. Mesalamine should only be used by nursing mothers if it is felt that the benefit of its use justifies the risk.

STORAGE: Store at room temperature, 15 C - 25 C (59 F - 77 F)

DOSING: The recommended dose is 2.4 g or 4.8 g once daily with a meal. Tablets should be swallowed whole without breaking the coating.

DRUG CLASS AND MECHANISM:

  • Mesalamine is an oral drug used for treating ulcerative colitis.
  • Lialda is mesalamine in a form that is slowly released in the intestine so that it can be given just once-a-day.
  • Other oral drugs containing mesalamine that are similar to Lialdainclude Asacol, Pentasa, and Apriso.
  • Asacol and Pentasa, however, are given as multiple daily doses.
  • The exact mechanism of mesalamine is not known but is believed to be by reducing inflammation in the colon.
  • Ulcerative colitis and other inflammatory diseases cause excessive production of chemicals (i.e., prostaglandins) that produce inflammation in the colon.
  • Prostaglandins are produced by cyclooxygenase and lipoxygenase enzymes.
  • These enzymes are over-active in individuals with ulcerative colitis.
  • Mesalamine may work by blocking the activity of cyclooxygenase and lipoxygenase, therefore, reducing the production of prostaglandins.
  • Reduced prostaglandin production reduces inflammation in the colon and other symptoms associated with ulcerative colitis.
  • The FDA approved Lialda in January 2007.

Medically reviewed by Eni Williams, PharmD

Reference: FDA Prescribing Information


Medically Reviewed by a Doctor on 1/22/2016


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index